HAP2 and P120 Biomarker Detection for Plasmodium Vivax Hypnozoites
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack reliable detection of Plasmodium vivax hypnozoites, which persist in the liver and cause recurrent malaria infections, hindering malaria eradication efforts due to undetectable latent stages and limitations in treating patients with glucose-6-phosphate dehydrogenase deficiency and pregnant women.
Innovation Solution
A method involving the detection of male gamete membrane fusion protein (HAP2) and proliferating cell nucleolar antigen P120 in extracellular vesicles secreted by liver cells, using size exclusion chromatography and affinity reagents to confirm the presence of these proteins, allowing for the identification of hypnozoite stages.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used, then general malaria detection is possible, but reliable detection of hypnozoites is not achieved
Solution Approach 1:
The patent uses extracellular vesicles (EVs) as intermediary carriers to detect hypnozoites. EVs are secreted by hypnozoite-infected liver cells and contain specific parasite proteins (HAP2 and P120) that serve as detectable markers. This intermediary approach allows indirect detection of dormant hypnozoites that cannot be directly visualized, thereby improving detection accuracy and reliability of latent infection diagnosis
Solution Approach 2:
The patent replaces traditional mechanical/light-based microscopy methods with molecular detection techniques. Instead of attempting to directly observe hypnozoites through conventional microscopy, the invention uses immunodetection methods (Western blotting, ELISA) to detect specific parasite proteins in EVs, substituting direct mechanical observation with biochemical detection that provides superior sensitivity and reliability for latent stage detection
2Reliability
If 8-aminoquinoline drugs are administered for radical cure, then hypnozoites are eliminated, but hemolytic anemia occurs in G6PDd patients
Solution Approach 1:
The patent applies preliminary diagnostic action before treatment. By detecting hypnozoites through EV protein markers (HAP2 and P120) before administering 8-aminoquinoline drugs, the system identifies which patients actually have latent infections requiring radical cure. This preliminary detection prevents unnecessary drug administration to patients without hypnozoites, including G6PDd patients who would be at risk for hemolytic anemia, while ensuring appropriate treatment for those who need it
Solution Approach 2:
The patent establishes a feedback loop where diagnostic information about hypnozoite presence (detected through EV protein markers) feeds into treatment decision-making. This feedback mechanism allows clinicians to adjust treatment plans based on actual infection status, avoiding harmful drug exposure in patients without latent infections while ensuring effective radical cure for those who have hypnozoites, thereby resolving the contradiction between treatment effectiveness and patient safety
3Productivity
If mass implementation of radical cure treatment is pursued, then relapse prevention is improved, but safety concerns arise for pregnant women and G6PDd patients
Solution Approach 1:
The patent implements preliminary screening of the entire population for hypnozoite presence using EV protein markers before offering radical cure treatment. This preliminary action enables selective treatment of only those individuals who actually harbor hypnozoites, rather than mass treatment of all individuals. Consequently, relapse prevention is achieved in the target population without exposing vulnerable groups (pregnant women and G6PDd patients) to unnecessary drug risks, thus improving productivity in relapse prevention while minimizing harmful effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables reliable detection of hypnozoites, facilitating targeted therapeutic interventions to eradicate latent infections and reduce malaria transmission, while avoiding adverse reactions in patients with glucose-6-phosphate dehydrogenase deficiency and pregnant women.
Implementation Method 1
The step of obtaining one or more EVs comprises performing size exclusion chromatography (SEC) on a sample containing EVs
Implementation Method 2
detecting the presence of HAP2 or P120 comprises contacting the one or more EVs with an affinity reagent that binds to HAP2 or P120, respectively
Data Source
AI summary
The present disclosure provides a method of detecting the presence of a hypnozoite stage of Plasmodium vivax in a liver cell. In addition, the present disclosure provides compositions and methods of detecting the presence of a latent Plasmodium vivax infection in a subject and for treating the subject detected to be infected.